Singapore, March 27 -- Polyplus (part of Sartorius, a distinguished upstream solutions provider for biologic and cell and gene therapy production and a part of the Sartorius group, has announced the introduction of pPLUS(R) AAV-RC2, a groundbreaking RepCap plasmid tailored for the production of adeno-associated virus vector 2 (AAV2). This launch is a significant addition to Polyplus's portfolio, aligning with the company's strategic direction to become a leading provider of critical raw materials for AAV production.

The pPLUS AAV-RC2 plasmid, now available off-the-shelf, is designed to streamline the manufacturing process for AAV vectors, offering a ready-to-use solution that enhances both efficiency and reliability in vector production....